Nuclea Biotechnologies secured an additional $4.2 million in Series D financing, bringing the company's total for that round to $40.3 million. The Massachusetts-based firm will use some of the money to launch its fatty acid synthase assays and other diagnostic tests.
Diagnostic-test maker gets additional $4.2M funding boost
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||